Ultragenyx Pharmaceutical
RARE
242 hedge funds and large institutions have $6.24B invested in Ultragenyx Pharmaceutical in 2021 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 78 increasing their positions, 90 reducing their positions, and 56 closing their positions.
4.38% less ownership
Funds ownership: 101.44% → 97.05% (-4.4%)
5% less funds holding
Funds holding: 255 → 242 (-13)
13% less repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 90
15% less call options, than puts
Call options by funds: $6.38M | Put options by funds: $7.52M
19% less capital invested
Capital invested by funds: $7.73B → $6.24B (-$1.49B)
23% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 56
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$95M |
| 2 |
Alkeon Capital Management
New York
|
+$62.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.2M |
| 4 |
Millennium Management
New York
|
+$58.7M |
| 5 |
ClearBridge Investments
New York
|
+$48.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$292M |
| 2 |
BlackRock
New York
|
-$205M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$40.4M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$39.9M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$27.2M |
RARE Hedge Fund Activity: Q2 2021 in Review
242 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2021, worth a combined $6.24B — down 19% from $7.73B a quarter earlier.
Sellers outnumbered buyers: 56 funds closed out of RARE and 43 opened new positions — a net loss of 13 holders — while 90 trimmed existing stakes and 78 added.
The largest buyer was Citadel Advisors, adding an estimated $95M. The largest seller was Capital Research Global Investors, cutting an estimated $292M.
- 242 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2021, down from 255 in Q1 2021.
- Funds reported $6.24B of Ultragenyx Pharmaceutical stock for Q2 2021, down 19% quarter-over-quarter.
- 43 funds opened new Ultragenyx Pharmaceutical positions in Q2 2021 and 56 closed out, a net change of -13 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2021 was Citadel Advisors, an estimated $95M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2021 was Capital Research Global Investors, an estimated $292M sold.
Based on aggregated 13F filings for Q2 2021.